Feed - Buzzberg

13:00
Jul 31 ◎

ABBV FY2026 Q2 Watch

AbbVie Inc. (ABBV) FY2026 Q2 Earnings Call

APGE ABBV ▾

Rob Michael

Acquisition target that AbbVie believes holds significant long-term potential in dermatology, respiratory, and other inflammatory diseases.

"our planned acquisition of Apogee Therapeutics, which represents an exciting opportunity to bolster AbbVie's leading immunology portfolio."

APGE WATCH

Rob Michael

Management raised full-year revenue and EPS guidance, indicating sustained strong momentum across key growth products, partly offset by anticipated (but non-core) near-term dilution from the Apogee acquisition.

"AVI delivered another excellent quarter, with results once again exceeding our expectations."

ABBV WATCH

HIGH

13:00
Apr 29 ◎

ABBV FY2026 Q1 Watch

AbbVie Inc. (ABBV) FY2026 Q1 Earnings Call

ABBV ▾

Rob Michael

Management is raising full-year EPS guidance based on strong momentum across key franchises, signaling a positive outlook for the remainder of the year.

"AbbVie is off to an excellent start to the year, with first quarter results exceeding our expectations across our diverse portfolio. We are delivering top-tier growth, and continue to strengthen our long-term outlook with pipeline"

ABBV WATCH

HIGH

14:00
Feb 04 ◎

ABBV FY2025 Q4 Watch

AbbVie Inc. (ABBV) FY2025 Q4 Earnings Call

JNJ ABBV BIIB LLY PFE ▾

Rob Michael

Skyrizi and Rinvoq combined 2026 sales guidance of $31B+ already surpasses the 2027 long-term goal of $30.5B, implying faster-than-expected immunology growth. — This suggests AbbVie is gaining share faster than expected in key indications (psoriasis, IBD), pressuring competitors like Eli Lilly (Omvoh) and J&J (Tremfya, Stelara).

"The main drivers of this growth include SkyRizzy and Renvoke, with combined sales of more than $31 billion, already surpassing our 2027 long-term guidance by half a billion."

JNJ WATCH

Rob Michael

Management is clearly bullish, raising 2026 revenue guidance to $67B (9.5% growth) and EPS to $14.37-$14.57, with multiple products (Skyrizi, Rinvoq, Vraylar, migraine portfolio) exceeding prior peak sales expectations.

"We are entering 2026 with substantial momentum and remain well-positioned to deliver another year of strong growth."

ABBV WATCH

Jeff Stewart

Vyalev (foslevodopa/foscarbidopa) is now expected to hit blockbuster status ($1B) in 2026, a year earlier than the prior >$1B peak guidance. — AbbVie's Parkinson's device franchise (Vyalev + Duopa) now has a peak sales potential of >$5B, competing directly with Biogen's approach in advanced Parkinson's.

"Given these insights and the robust early launch trends globally, we now expect Vylev to achieve blockbuster revenue in 2026."

BIIB WATCH

Rob Michael

The IL-23 category in IBD is expanding rapidly, but Skyrizi's frontline capture rate is ~75% in IBD overall and ~80% in Crohn's, showing no impact from newer competitors. — This indicates Eli Lilly's Omvoh is largely gaining second-line share, not capturing new frontline patients, limiting its potential to displace Skyrizi in the most valuable first-line segment.

"The main drivers of this growth include SkyRizzy and Renvoke, with combined sales of more than $31 billion, already surpassing our 2027 long-term guidance by half a billion."

LLY WATCH

Rob Michael

The oral CGRP franchise (Ubrelvy + Qulipta) is outperforming prior peak guidance, with 2026 revenue forecast at $2.9B vs. >$3B prior peak, pressuring Pfizer's Nurtec in the acute and preventive migraine space. — AbbVie's faster-than-expected migraine growth directly challenges Pfizer's Nurtec, which is facing patent expiry and increased competition in a primary care setting.

"As I mentioned before, as we look at these brands, we would expect them to exceed $5 billion now."

PFE WATCH

HIGH

Feed — Buzzberg